Lori Firmani sold $1,469 of DMRA
Interim CFO at Damora Therapeutics, Inc.. 261 shares at an average of $5.63, traded Jan 3, 2025, filed Jan 7, 2025.
Score components
- +22RoleCFO
- 0Trade size$1k at market
- +10Share of holdings soldSold 36% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.0%, 3m -59.3%, 6m -39.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-002813, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 3, 2025 | MOption exercise Common Stock | +726 | - | - | 726 | Jan 7, 2025 |
| Jan 3, 2025 | SOpen-market sale Common Stock | -261 | $5.63 | $1,469 | 465 | Jan 7, 2025 |
| Jan 3, 2025 | MOption exercise Restricted Stock Unitsderivative | -726 | $0.00 | $0 | 1,474 | Jan 7, 2025 |
| Jan 3, 2025 | AGrant or award Stock Option (right to buy)derivative | +5,000 | $0.00 | $0 | 5,000 | Jan 7, 2025 |
Related signals
Other insiders at Damora Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | DMRAbuy Damora Therapeutics, Inc. | Jennifer Jarrett Director, President and CEO | $253k 12,500 shares | +3% | |
| 0Weak | DMRAsell Damora Therapeutics, Inc. | Garrett Winslow General Counsel | $7,345 245 shares | -10% | |
| 27Weak | Damora Therapeutics, Inc. | Lori Firmani Chief Financial Officer | $2,890 135 shares | -13% | |
| 20Weak | Damora Therapeutics, Inc. | Garrett Winslow General Counsel | $5,452 255 shares | -12% | |
| 30Weak | Damora Therapeutics, Inc. | Hans T. Schambye Chief Executive Officer | $15k 700 shares | -13% | |
| 27Weak | Damora Therapeutics, Inc. | Lori Firmani Interim CFO | $498 147 shares | -18% | |
| 20Weak | Damora Therapeutics, Inc. | Garrett Winslow General Counsel | $881 260 shares | -15% | |
| 30Weak | Damora Therapeutics, Inc. | Hans T. Schambye Chief Executive Officer | $2,484 735 shares | -15% | |
| 35Weak | Damora Therapeutics, Inc. | Hans T. Schambye Chief Executive Officer | $7,510 1,341 shares | -28% | |
| 25Weak | Damora Therapeutics, Inc. | Garrett Winslow General Counsel | $2,638 471 shares | -32% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.